Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057380 · ClinicalTrials.gov registry record · Phase 2
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
A Phase 2 study of Advanced Solid Tumors, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 12
- Study locations
NCT02057380 is a Phase 2 study of Advanced Solid Tumors that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 13 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT02057380, a Phase 2 study of Advanced Solid Tumors, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG paclitaxel
- DRUG linsitinib
- DRUG erlotinib
Study Locations (12)
Other
- Site CZ42001 - Ostrava-Poruba
- Site DE49002 - Berlin
- Site DE49001 - Würzburg
- Site SG65002 - Singapore
- Site TH66003 - Khon Kaen
California
- Site US10004 - La Jolla
Florida
- Site US10006 - Tampa
Maryland
- Site US10002 - Baltimore
Michigan
- Site US10008 - Ann Arbor
Oklahoma
- Site US10001 - Oklahoma City
Rio Grande do Sul
- Site BR55005 - Porto Alegre
West Pomeranian Voivodeship
- Site PL48001 - Szczecin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-04-16 |
| Est. Completion | 2016-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057380
The ClinicalTrials.gov registry entry for NCT02057380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT02057380 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02057380 about?
NCT02057380 is a clinical study titled "A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial". The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
What is the current status of trial NCT02057380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2014-04-16. Estimated completion is 2016-12-21.
What conditions does trial NCT02057380 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT02057380?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), paclitaxel (DRUG), linsitinib (DRUG), erlotinib (DRUG).
Who is sponsoring clinical trial NCT02057380?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02057380 being conducted?
This trial has 12 study locations across California, Florida, Maryland, Michigan, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
RECRUITING · Phase 2
-
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
RECRUITING · Phase 2
-
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.